Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline through a $2.2 billion acquisition of autoimmune biotech company Forte Biosciences.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Argenx has announced its intent to acquire Forte Biosciences for $2.2 billion. The deal is aimed at strengthening Argenx's push into immunology and autoimmune treatments.
Coverage from GlobeNewswire, FirstWord Pharma, Endpoints News, Fierce Biotech, and the Wall Street Journal emphasizes the acquisition of FB102, a first-in-class anti-CD122 antibody. Fierce Biotech specifically notes that this drug is currently in phase 2 development for the treatment of vitiligo.
Future developments depend on the integration of FB102 into the Argenx immunology pipeline and the progression of the phase 2-stage drug.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
How much is Argenx paying for Forte Biosciences?
The acquisition price is $2.2 billion.
What specific asset is Argenx acquiring?
Argenx is acquiring FB102, which is described as a first-in-class anti-CD122 antibody.
What is the current status of the drug FB102?
According to Fierce Biotech, the drug is in phase 2 and is intended for the treatment of vitiligo.
Coverage (6)
- Argenx to acquire Forte Biosciences for $2.2B Axios · 11h ago
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline GlobeNewswire · 11h ago
- argenx to buy Forte Bio for $2.2B in immunology push FirstWord Pharma · 11h ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Endpoints News · 11h ago
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Fierce Biotech · 11h ago
- Argenx to Buy Forte Biosciences for $2.2 Billion WSJ · 11h ago broke it first
People, places & organizations
Topics
Related trends
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares slide despite second-quarter earnings and revenue beats, driven by softness in its biotech unit.
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits
8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Researchers and investors are evaluating new clinical data from Biogen as the firm explores tau-targeting treatments for Alzheimer’s disease.
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio shares see significant gains following the release of positive 36-week trial data for its experimental alopecia areata drug, Bempikibart.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk and Vivani have announced a partnership to develop a long-acting semaglutide implant designed to assist with long-term weight loss.